Evommune, Inc. announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. for the drug candidate EVO570. The agreement grants Evommune worldwide rights, excluding Greater China, to develop, manufacture, and commercialize the novel therapy for inflammatory diseases.
Key Details
- Agreement: Exclusive license agreement with Hinova Pharmaceuticals Inc. for the investigational drug EVO570 (formerly HC118).
- Drug Candidate: EVO570 is a potential best-in-class oral VAV1-directed molecular glue degrader (MGD) with a planned development path in rheumatoid arthritis.
- Terms & Territory: Evommune obtains worldwide rights to develop, manufacture, and commercialize EVO570, excluding Greater China. Financial terms of the transaction were not disclosed in the filing.